Last reviewed · How we verify

Dexmedetomidine and propofol

Ain Shams University · FDA-approved active Small molecule

Dexmedetomidine and propofol are combined sedative agents that work synergistically to produce sedation and anesthesia through alpha-2 adrenergic receptor agonism and GABA-A receptor potentiation, respectively.

Dexmedetomidine and propofol are combined sedative agents that work synergistically to produce sedation and anesthesia through alpha-2 adrenergic receptor agonism and GABA-A receptor potentiation, respectively. Used for Sedation in intensive care units, Procedural sedation, Perioperative sedation and anesthesia.

At a glance

Generic nameDexmedetomidine and propofol
Also known asPrecedex, Diprivan, Dexmedetomidine Hydrochloride injection and propofol injectable emulsion, DEX+PR, DxPr
SponsorAin Shams University
Drug classSedative-hypnotic combination
TargetAlpha-2 adrenergic receptor (dexmedetomidine); GABA-A receptor (propofol)
ModalitySmall molecule
Therapeutic areaAnesthesia and Sedation
PhaseFDA-approved

Mechanism of action

Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Propofol is a GABA-A receptor positive allosteric modulator that enhances inhibitory neurotransmission, producing rapid sedation and hypnosis. The combination leverages complementary mechanisms to achieve balanced sedation with potentially reduced dosing requirements for each agent.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: